View Post

Real-world effectiveness may not reflect trial efficacy for HER2-targeted agents

In Clinical Studies News by Barbara Jacoby

By: Laura Cowen From: medwirenews.com Women receiving first-line pertuzumab or second-line trastuzumab emtansine (T-DM1) for HER2-positive metastatic breast cancer have lower than expected survival times in clinical practice when compared with pivotal trials, researchers report. Writing in JAMA Oncology, Josee-Lyne Ethier (Queen’s University, Kingston, Ontario, Canada) and co-authors suggest that the “differences in outcome likely reflect differences in patient population …

View Post

Therapeutic target discovery could improve breast cancer treatments

In In The News by Barbara Jacoby

By: Anna Begley From: drugtargetreview.com Research by a team in Canada reveals a promising therapeutic target to counter HER2-positive breast cancer. New research by a team at Université de Montréal (UdeM), Canada, has revealed a highly promising therapeutic target that could lead to better treatments of HER2-positive breast cancer. In this breast cancer, a gene called HER2 is expressed, promoting …

View Post

Promising new research on aggressive breast cancer

In In The News by Barbara Jacoby

Source: University of Montreal From: eurekalert.org Better treatments of HER2-positive breast cancer are closer at hand, thanks to new research by a team led by Université de Montréal professor Jean-François Côté at the cytoskeleton organization and cell-migration research unit of the UdeM-affiliated Montreal Clinical Research Institute. Published in PNAS, the journal of the U.S. National Academy of Sciences, the new …

View Post

Knight Therapeutics Announces Health Canada Approval for NERLYNX® (Neratinib) to Treat HER2-Positive Metastatic Breast Cancer

In Clinical Studies News by Barbara Jacoby

Source: Knight Therapeutics From: finance.yahoo.com Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved NERLYNX® (neratinib) in combination with capecitabine for the treatment of adult patients with metastatic HER2-overexpressed/amplified breast cancer, who have received two or more prior anti-HER2-based regimens in the metastatic setting. The approval was based on results …

View Post

MNT Investigates: Anti-HER2 drugs and the fight against metastatic breast cancer

In In The News by Barbara Jacoby

From: medicalnewstoday.com HER2-positive breast cancer occurs when cancer cells have excessive amounts of a growth-promoting protein called human epidermal growth factor receptor 2 (HER2). The protein causes the tumor cells to grow and multiply, making these breast cancers aggressive and fast-spreading. About 1 in 5 women with breast cancer have HER2-positive breast cancers. Anti-HER2 drugs are therapies developed to target …

View Post

Neratinib Improve OS and CNS-Related Outcomes in Early-Stage HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Nichole Tucker From: targetedonc.com Treatment with neratinib demonstrated a modest overall survival benefit in patients with HER2-positive breast cancer compared with placebo, according to the long-term OS and central nervous system results from the phase 3 ExteNET trial Treatment with the irreversible pan-HER inhibitor neratinib (Nerlynx) demonstrated a modest overall survival (OS) benefit in patients with HER2-positive breast cancer …

View Post

Innovations in the Treatment of HER2+ Breast Cancer

In In The News by Barbara Jacoby

By: Sara Karlovitch From: targetedonc.com In an interview with Targeted Oncology, Komal Jhaveri, MD, FACP, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses HER2-positive metastatic breast cancer innovations, treatments, and upcoming studies. Major advances have been made in the HER2-positive breast cancer space in both the first-line and later-line settings. First, in 2015, the results from the CLEOPATRA …

View Post

Rare Patient Voice: Paid Opportunity for HER2 Positive Breast Cancer Patients

In Paid Opportunities For The Cancer Community by Barbara Jacoby

Study Details: 10 min Online Survey Compensation $20 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay $100 an hour for it! Signup Today and let YOUR Voice be heard! Why …

View Post

Meisel on Managing Toxicities With T-DM1 in HER2+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Courtney Marabella From: onclive.com Data from the pivotal phase 3 KATHERINE (NCT01772472) has led to the addition of ado-trastuzumab emtansine (T-DM1; Kadcyla) to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it, according to Jane L. Meisel, MD. The phase 3 KATHERINE trial …

View Post

New five-minutes treatment for breast cancer rolled out in UK by National Health Service

In In The News by Barbara Jacoby

From: businessinsider.in A novel breast cancer treatment that takes just five minutes instead of the current two and a half hours has been launched across the UK by the National Health Service (NHS) England. The injection called Phesgo will be offered to eligible patients with HER2-positive breast cancer, undergoing chemotherapy. It takes as little as five minutes to prepare and …